QQQ   377.93 (+1.02%)
AAPL   148.64 (-0.03%)
MSFT   308.13 (-0.33%)
FB   328.69 (+1.26%)
GOOGL   2,748.94 (-0.09%)
TSLA   1,024.86 (+12.66%)
AMZN   3,320.37 (-0.46%)
NVDA   231.66 (+1.94%)
BABA   176.17 (-0.86%)
NIO   41.27 (+6.15%)
CGC   13.57 (+1.42%)
GE   105.43 (+1.33%)
AMD   122.36 (+2.12%)
MU   68.76 (+1.85%)
T   25.64 (+0.59%)
F   16.00 (-1.72%)
ACB   7.18 (+1.56%)
DIS   172.01 (+1.53%)
PFE   43.15 (-0.02%)
BA   212.87 (-0.05%)
AMC   36.83 (+0.63%)
QQQ   377.93 (+1.02%)
AAPL   148.64 (-0.03%)
MSFT   308.13 (-0.33%)
FB   328.69 (+1.26%)
GOOGL   2,748.94 (-0.09%)
TSLA   1,024.86 (+12.66%)
AMZN   3,320.37 (-0.46%)
NVDA   231.66 (+1.94%)
BABA   176.17 (-0.86%)
NIO   41.27 (+6.15%)
CGC   13.57 (+1.42%)
GE   105.43 (+1.33%)
AMD   122.36 (+2.12%)
MU   68.76 (+1.85%)
T   25.64 (+0.59%)
F   16.00 (-1.72%)
ACB   7.18 (+1.56%)
DIS   172.01 (+1.53%)
PFE   43.15 (-0.02%)
BA   212.87 (-0.05%)
AMC   36.83 (+0.63%)
QQQ   377.93 (+1.02%)
AAPL   148.64 (-0.03%)
MSFT   308.13 (-0.33%)
FB   328.69 (+1.26%)
GOOGL   2,748.94 (-0.09%)
TSLA   1,024.86 (+12.66%)
AMZN   3,320.37 (-0.46%)
NVDA   231.66 (+1.94%)
BABA   176.17 (-0.86%)
NIO   41.27 (+6.15%)
CGC   13.57 (+1.42%)
GE   105.43 (+1.33%)
AMD   122.36 (+2.12%)
MU   68.76 (+1.85%)
T   25.64 (+0.59%)
F   16.00 (-1.72%)
ACB   7.18 (+1.56%)
DIS   172.01 (+1.53%)
PFE   43.15 (-0.02%)
BA   212.87 (-0.05%)
AMC   36.83 (+0.63%)
QQQ   377.93 (+1.02%)
AAPL   148.64 (-0.03%)
MSFT   308.13 (-0.33%)
FB   328.69 (+1.26%)
GOOGL   2,748.94 (-0.09%)
TSLA   1,024.86 (+12.66%)
AMZN   3,320.37 (-0.46%)
NVDA   231.66 (+1.94%)
BABA   176.17 (-0.86%)
NIO   41.27 (+6.15%)
CGC   13.57 (+1.42%)
GE   105.43 (+1.33%)
AMD   122.36 (+2.12%)
MU   68.76 (+1.85%)
T   25.64 (+0.59%)
F   16.00 (-1.72%)
ACB   7.18 (+1.56%)
DIS   172.01 (+1.53%)
PFE   43.15 (-0.02%)
BA   212.87 (-0.05%)
AMC   36.83 (+0.63%)
TSE:MDNA

Medicenna Therapeutics Stock Forecast, Price & News

C$2.80
-0.20 (-6.67 %)
(As of 10/25/2021 12:00 AM ET)
Add
Compare
Today's Range
C$2.80
▼
C$2.94
50-Day Range
C$2.42
▼
C$3.57
52-Week Range
C$2.35
▼
C$7.02
Volume73,998 shs
Average Volume84,851 shs
Market CapitalizationC$150.48 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
View Price History Chart DataSkip Price History Chart
30 days | 90 days | 365 days | Advanced Chart
Receive MDNA News and Ratings via Email

Sign-up to receive the latest news and ratings for Medicenna Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


About Medicenna Therapeutics

Medicenna Therapeutics Corp., a clinical stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase 2b clinical trial for the treatment of recurrent glioblastoma (rGBM), as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA55, which has completed Phase 2b clinical trial to treat rGBM; MDNA109, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease (GvHD); MDNA413, a dual IL-4/IL-13 antagonist to treat solid tumors; and MDNA132, an IL-13 Superkine to chimeric antigen receptor T (CAR-T) platform. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, or naked IL-2, IL-4, and IL-13 Superkines. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.

Headlines

We Think Medicenna Therapeutics (TSE:MDNA) Can Afford To Drive Business Growth
July 20, 2021 |  finance.yahoo.com
MDNA: Phase 1 Trial of MDNA11 to Initiate in 3Q21…
June 2, 2021 |  finance.yahoo.com
Medicenna Announces the Peer-Reviewed Publication of Clinical Data from Phase 2b Trial Evaluating MDNA55 in Recurrent Glioblastoma
May 7, 2021 |  finance.yahoo.com
Medicenna to Present at the Bloom Burton & Co. Healthcare Investor Conference
April 14, 2021 |  finance.yahoo.com
Medicenna Therapeutics Corp. (MDNA)
January 10, 2021 |  realmoney.thestreet.com
Why Sonoma, Medicenna And Dare Bioscience Are Trading Higher Today
December 18, 2020 |  msn.com
Companies Like Medicenna Therapeutics (TSE:MDNA) Are In A Position To Invest In Growth
December 4, 2020 |  finance.yahoo.com
Medidata Synthetic Control Arm® Supported by the US Food and Drug Administration (FDA) for Use in Medicenna Therapeutics, Corp. Phase 3 Registrational Trial in Recurrent ...
October 30, 2020 |  businesswire.com
Medicenna Provides MDNA55 rGBM Clinical Program Update Following Positive End of Phase 2 Meeting with the U.S. Food and Drug Administration (FDA)
October 15, 2020 |  markets.businessinsider.com
Medicenna to Commence Trading on Nasdaq
August 20, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange
TSE
Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
TSE:MDNA
Previous Symbol
CUSIP
N/A
CIK
N/A
Web
www.medicenna.com
Phone
+1-403-6807898
Employees
2,021
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
C$0.62 per share
Price / Cash Flow
4.49
Book Value
C$0.60 per share
Price / Book
4.64

Profitability

EPS (Most Recent Fiscal Year)
N/A
Net Income
N/A
Net Margins
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
0.07
Current Ratio
7.51
Quick Ratio
7.43

Price-To-Earnings

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A

Miscellaneous

Outstanding Shares
53,742,000
Market Cap
C$150.48 million
Next Earnings Date
11/11/2021 (Estimated)
Optionable
Not Optionable

MarketRank™

Overall MarketRank™

1.58 out of 5 stars

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Medicenna Therapeutics (TSE:MDNA) Frequently Asked Questions

Is Medicenna Therapeutics a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Medicenna Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Medicenna Therapeutics stock.
View analyst ratings for Medicenna Therapeutics or view top-rated stocks.

What stocks does MarketBeat like better than Medicenna Therapeutics?

Wall Street analysts have given Medicenna Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Medicenna Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Medicenna Therapeutics' next earnings date?

Medicenna Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 11th 2021.
View our earnings forecast for Medicenna Therapeutics.

How has Medicenna Therapeutics' stock price been impacted by Coronavirus?

Medicenna Therapeutics' stock was trading at C$3.02 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MDNA stock has decreased by 7.3% and is now trading at C$2.80.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for MDNA?

2 brokerages have issued 12-month price objectives for Medicenna Therapeutics' stock. Their forecasts range from C$9.00 to C$11.00. On average, they anticipate Medicenna Therapeutics' share price to reach C$10.00 in the next year. This suggests a possible upside of 257.1% from the stock's current price.
View analysts' price targets for Medicenna Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Medicenna Therapeutics' key executives?

Medicenna Therapeutics' management team includes the following people:
  • Dr. Fahar Merchant, Founder, Chairman, CEO & Pres (Age 64, Pay $410.99k)
  • Ms. Rosemina Merchant, Founder, Chief Devel. Officer & Director (Age 64, Pay $319.88k)
  • Ms. Elizabeth Williams CPA, CA, CFO & Corp. Sec. (Age 43, Pay $225k)
  • Dr. Kevin Moulder Ph.d., Chief Scientific Officer
  • Dr. John H. Sampson M.D., Ph.D., MBA, Chief Clinical Advisor
  • Dr. Mann Muhsin M.D., Chief Medical Officer
  • Dr. Samuel R. Denmeade, Scientific Advisor

What other stocks do shareholders of Medicenna Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medicenna Therapeutics investors own include OPKO Health (OPK), AbbVie (ABBV), Livongo Health (LVGO), Aptose Biosciences (APTO), (ATE), Birchcliff Energy (BIR), CVS Health (CVS), Freehold Royalties (FRU), Fastly (FSLY) and Inovio Pharmaceuticals (INO).

What is Medicenna Therapeutics' stock symbol?

Medicenna Therapeutics trades on the Toronto Stock Exchange (TSX) under the ticker symbol "MDNA."

How do I buy shares of Medicenna Therapeutics?

Shares of MDNA and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Medicenna Therapeutics' stock price today?

One share of MDNA stock can currently be purchased for approximately C$2.80.

How much money does Medicenna Therapeutics make?

Medicenna Therapeutics has a market capitalization of C$150.48 million.

How many employees does Medicenna Therapeutics have?

Medicenna Therapeutics employs 2,021 workers across the globe.

What is Medicenna Therapeutics' official website?

The official website for Medicenna Therapeutics is www.medicenna.com.

Where are Medicenna Therapeutics' headquarters?

Medicenna Therapeutics is headquartered at 2440 Kensington Rd NW, CALGARY, AB T2N 3S1, Canada.

How can I contact Medicenna Therapeutics?

Medicenna Therapeutics' mailing address is 2440 Kensington Rd NW, CALGARY, AB T2N 3S1, Canada. The company can be reached via phone at +1-403-6807898.


This page was last updated on 10/25/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.